Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Heather Wakelee, MD
Considerations for Immunotherapy Duration in NSCLC: Dr Heather Wakelee

September 11th 2024

Heather Wakelee, MD, Stanford University, discusses the pros and cons of different durations of immunotherapy in non-small cell lung cancer (NSCLC) and the future outlook for patient-specific care.

Diverse representation in health care materials is one of multiple factors that could benefit patient education initiatives | image credit: Fitry - stock.adobe.come
Different Options for Different People: Dr Bellinda King-Kallimanis Explores the State of Patient Education in Lung Cancer

September 10th 2024

Sandip Patel, MD
Dr Sandip Patel Previews the Highly Anticipated 50th Anniversary of WCLC

September 6th 2024

Lung cancer | Image credit: Sebastian Kaulitzki - stock.adobe.com
Late-Stage Vibostolimab, Pembrolizumab Plus Chemotherapy Trial Discontinued Due to Adverse Events

August 8th 2024

AJMC
Shared Decision-Making for Lung Cancer Screening: More Straw for the Camel’s Back

May 31st 2024

Key Updates in the Management of Small Cell Lung Cancer

Explore recent advances in small cell lung cancer management, including staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery with this Peer Exchange.

Explore recent advances in small cell lung cancer management, including staging, treatment options across disease stages, emerging therapies, biomarker testing, and strategies to overcome challenges in diagnosis and care delivery with this Peer Exchange.

More News

Image of a lung scan
June 24th 2022

Survival Rates Have Improved, but Disparities Persist in SCLC

Jared Kaltwasser
Patients who received a diagnosis of small cell lung cancer (SCLC) between 2010 and 2016 had a nearly 2% increase in overall survival vs those who received their diagnosis between 2004 and 2010.
Unmet Needs in NSCLC Treatment
June 22nd 2022

Unmet Needs in NSCLC Treatment

Three medical experts highlight unmet needs they routinely run into while treating patients with NSCLC.
An Overview of NSCLC and Actionable Mutations
June 22nd 2022

An Overview of NSCLC and Actionable Mutations

Joshua Sabari, MD, provides a breakdown of advanced non-small cell lung cancer (NSCLC) and its actionable mutations.
SSc-ILD Treatment Landscape and Clinical Trials
June 21st 2022

SSc-ILD Treatment Landscape and Clinical Trials

Dr Kristin Highland continues the treatment landscape discussion, focusing on systemic sclerosis ILD (SSc-ILD) and clinical trial data that studied therapy options for IPF, PF-ILD, and SSc-ILD.
IPF, PF-ILD Treatment Landscape
June 21st 2022

IPF, PF-ILD Treatment Landscape

The panel provides an overview of the treatment landscape for idiopathic pulmonary fibrosis (IPF) and progressing fibrosing ILD (PF-ILD).
Image of clinicians consulting
June 18th 2022

CSCC Case Raises Questions About Implications of Early Response to Cemiplimab

Jared Kaltwasser
A patient’s quick response to cemiplimab (Libtayo) was reversed after the therapy was stopped due to progression of apparent metastatic cutaneous squamous cell carcinoma.
Image of lung cancer research
June 16th 2022

Durvalumab Timing Might Affect Pneumonitis Risk Following Chemoradiotherapy in NSCLC

Jared Kaltwasser
The study, based on a case series in Japan, found the risk of grade 2 or above chemoradiation increased when durvalumab was started within 14 days of the final thoracic radiotherapy treatment.
Treatment Goals for Patients With ILD
June 14th 2022

Treatment Goals for Patients With ILD

Drs Noble and Highland explain the typical treatment goals physicians aim for when looking at ILD therapy options.
ILD Clinical and Economic Burden
June 14th 2022

ILD Clinical and Economic Burden

Ryan Haumschild, PharmD, MS, MBA, and Kristin Highland, MD, explain the clinical and economic burdens associated with ILD treatment.
Image of genetic research
June 11th 2022

Standardized Uptake Values Correlate With PD-L1 Expression in Stage IV Lung Adenocarcinoma

Jared Kaltwasser
The study suggests standardized uptake values may be a useful marker to predict treatment response and prognosis in lung adenocarcinoma.
Image of genetic material for analysis
June 9th 2022

RNA-Binding Protein Signature Could Help Stratify Risk in Lung Adenocarcinoma

Jared Kaltwasser
A new model may be able to better identify which patients will respond to immunotherapy.
Who is Diagnosing and Treating ILD?
June 7th 2022

Who is Diagnosing and Treating ILD?

Daniel Culver, DO, and Paul Noble, MD, highlight the types of physicians who manage patients with different forms of ILD, from diagnosis to treatment, as well as the process of referrals.
Incidence and Prevalence For ILD
June 7th 2022

Incidence and Prevalence For ILD

Daniel Culver, DO, and Paul Noble, MD, talk about incidence and prevalence typically seen with patients with ILD.
Graphic of lungs
June 3rd 2022

Pulmonary Function at NSCLC Diagnosis May Impact Overall Survival

Jaime Rosenberg
Drawing on data from more than 2000 patients, the researchers of the retrospective study found that pulmonary function test results were associated with overall survival in non-small cell lung cancer (NSCLC).
lung icon
May 30th 2022

Understanding Treatment of Leptomeningeal Disease in NSCLC

Gianna Melillo
Researchers assessed treatment patterns and outcomes of patients with non-small cell lung (NSCLC) cancer and leptomeningeal disease exposed to osimertinib.
person smoking
May 26th 2022

Assessing Tobacco Exposure Among Former Smokers Eligible for Lung Cancer Screening

Gianna Melillo
Results of a cross-sectional study showed former smokers eligible for lung cancer screening should be asked about recent tobacco use and exposure, while counseling about the harms of these 2 risk factors is warranted.
world icons
May 20th 2022

Study Documents Rise in Global Lung Cancer Rates Over 30 Years

Gianna Melillo
An analysis of data from the 2019 Global Burden of Disease Study revealed wide variations in lung cancer rates seen throughout the world over the past 30 years.
almonds
May 17th 2022

Diet Created to Lower Diabetes Risk Linked With Reduced Lung Cancer Incidence

Gianna Melillo
The findings are based off an analysis of 98,159 individuals.
Rural area.
May 12th 2022

Study Finds Rural Residence May Adversely Influence Lung Cancer Screening Among Veterans

Matthew Gavidia
Veterans residing in rural areas were less likely to complete annual repeat lung cancer screenings compared with those living in a nonrural location, with reduced uptake of initial lung cancer screening also found among eligible veterans in rural vs nonrural locations.
operating table
May 9th 2022

Survival Varies Little by Surgery Type in NSCLC With Micro Lesions

Jared Kaltwasser
A subsequent analysis suggested, however, that segmentectomy was preferable to lobectomy in many cases.
smokey lungs
May 3rd 2022

Meta-analysis Finds Link Between Emphysema Severity, Lung Cancer Risk

Gianna Melillo
A new meta-analysis found that more severe emphysema is associated with an increased risk of lung cancer.
lung graphic
May 1st 2022

Review Outlines Advancements in Precision Therapy for Metastatic Lung Cancer

Gianna Melillo
A new review article summarizes current approaches to precision medicine in lung cancer.
Image of lungs
April 30th 2022

Study Finds Risk of Overinvestigation in Patients With Lung Cancer Not Fit for Anticancer Treatment

Jaime Rosenberg
Among a group of patients with lung cancer who were not suitable for anticancer treatment, the researchers found that 40% underwent additional investigations after their initial CT scan before eventually receiving best supportive care.
doctor speaking with patient
April 29th 2022

Outreach Efforts Increased Lung Cancer Screening in Primary Care Settings

Gianna Melillo
Researchers in Pennsylvania conducted a randomized controlled trial to understand the effect of patient outreach on lung cancer screening rates.
Melissa Johnson, MD
April 26th 2022

Dr Melissa Johnson Highlights Potential Lung Cancer Treatments in the Pipeline

Gianna Melillo Matthew Gavidia
Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the potential of certain drug classes for lung cancer.
New Study Details Frequency of SDOH Documentation Among Patients With Lung Cancer
April 22nd 2022

New Study Details Frequency of SDOH Documentation Among Patients With Lung Cancer

Jaime Rosenberg
A decade’s worth of data included more than 5 million social determinants of health (SDOH) attributes across nearly 2 million clinical notes from the patient visits extrapolated from a natural language processing system.
Davey Daniel.
April 17th 2022

Dr Davey Daniel on Barriers Limiting Genomic Testing Use in Lung Cancer

Matthew Gavidia
Davey Daniel, MD, chief medical officer, OneOncology, speaks on the knowledge, infrastructure, and payer-related barriers that are limiting the use of genomic testing in the management of patients with lung cancer.
OneOncology’s Arrowsmith Looks Forward to Real-time Dynamics in Clinical Pathways
April 14th 2022

OneOncology’s Arrowsmith Looks Forward to Real-time Dynamics in Clinical Pathways

Mary Caffrey
Across OneOncology, says Edward Arrowsmith MD, MPH, clinical pathways offer a vehicle for physicians to agree on best practices and to implement them across the network. Early this year, Arrowsmith became medical director for Clinical Pathways, OneOncology.
scale
April 11th 2022

Excess Body Fat Linked With Increased Risk of Radiation Pneumonitis in NSCLC

Gianna Melillo
Findings suggest measuring excess weight in patients may help predict the development of radiation pneumonitis.
smoke in lungs
April 6th 2022

Real-world Data Show Benefits of Increased Lung Cancer Screening but Persistent Disparities

Gianna Melillo
Although the widespread use of low dose computed tomography screening for lung cancer has led to improved mortality in recent years, disparities in uptake persist throughout the United States.
<123456789>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo